FUJIFILM Cellular Dynamics signs agreement with IASO Biotherapeutics

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced that it has entered an agreement to grant global healthcare company IASO Biotherapeutics USA Limited a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.

Under the agreement, IASO Bio will have a non-exclusive license to use the iPSC cell lines for research and development purposes and to utilize GMP-grade cell lines for clinical and commercial manufacture and commercialization of iPSC-derived cell therapies. Terms of the agreement were not disclosed.

Over the past few years, FUJIFILM Cellular Dynamics has licensed its iPSC platform to numerous leading biotech companies including, Cynata Therapeutics Limited, Sana Biotechnology, Novo A/S, among others.
MB Bureau